Skip to content
  1. Home/
  2. Latest news

Latest news

Using your own cells to fight cancer

Cell therapy is bringing the world one step closer to eliminating cancer. Here’s how Johnson & Johnson is moving this cutting-edge therapy forward.

Johnson & Johnson named to Fortune‘s 2025 America’s Most Innovative Companies list

The company’s commitment to developing solutions that tackle the world’s most pressing health challenges has helped Johnson & Johnson be recognized as the top-ranked healthcare company on the list.

More from Johnson & Johnson

The future of immunology

Learn about the advances Johnson & Johnson is making to potentially help treat the millions of people living with conditions in which the immune system mistakenly damages healthy cells in the body.

Meet two Johnson & Johnson nurse educators dedicated to teaching cancer care providers

Jennifer Huff and Jacqui Mellott are two of Johnson & Johnson’s oncology clinical educators—a team of 50 nurses who visit hospitals and infusion centers to help providers understand and stay up to date with treatments.

Careers

Looking for a career opportunity at Johnson & Johnson? Search our available jobs.

Inside Johnson & Johnson’s decades-long quest to develop effective treatments for IBD

Inflammatory bowel disease doesn’t have a cure—yet. But the recent FDA approval of a promising medication is the latest in a long line of treatments from Johnson & Johnson that are helping patients with IBD.

What is metastatic cancer?

The number of people living with this advanced form of cancer is on the rise. Learn how Johnson & Johnson is pioneering innovations to help patients live longer.

“The surgical devices I design help speed healing and save lives”

Candice Otrembiak’s work combines her love of science with her natural problem-solving skills. The result: high-tech devices that help make medical procedures more efficient for surgeons and safer for patients.

Press releases

U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma

ODAC recommendation based on the positive progression-free survival and clinical benefit in the Phase 3 AQUILA study If approved, DARZALEX FASPRO® would be the first treatment to potentially delay or prevent progression to multiple myeloma

Shockwave Medical Study Confirms Benefit of IVL-First Strategy in Real-World Female Patients with Complex Calcified Lesions in Late-Breaking Data Presentation at EuroPCR 2025

EMPOWER CAD, a global prospective, multi-center, real-world study, reaffirms favorable acute outcomes for coronary IVL in female patients, unlike other calcium modification tools

Shockwave Medical Highlights Commitment to Transform Treatment of Cardiovascular Disease at EuroPCR 2025

23 abstracts, including three late-breaking data presentations, to underscore the company’s scientific leadership in IVL and Reducer technology and the strength of its portfolio

New Breast Implant Closes the Reconstruction Gap for 1 in 7 Women After Breast Cancer Surgery

MENTOR™ MemoryGel™ Enhance Breast Implants are the first and only implant designed to meet the reconstruction needs of women with larger breast sizes who have undergone a mastectomy Patients who previously lacked access to proportionately sized implants for reconstruction are now afforded the same clinical benefits that have long been available to others

Icotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis

66% of patients with scalp psoriasis and 77% with genital psoriasis treated with investigational icotrokinra achieved site-specific clear or almost clear skin at Week 16 Icotrokinra continues to demonstrate a standout combination of significant skin clearance (IGA 0/1) and a favorable safety profile in a once daily pill

More from Johnson & Johnson

What are clinical trials?

Behind every innovative medicine, treatment and therapy is a clinical trial. To help you understand them better, here’s a closer look at how they work.

Johnson & Johnson named a 2025 Fortune World’s Most Admired Company

A dedication to innovation and social responsibility are just two of the qualities that helped the company garner a coveted spot on the list for the 23rd year in a row.